11-01 :: December 2010 / January 2011
nanotimes
Companies Facts
departments to form a Global Drug Discovery orga- nization. The expanded organization will be led by Bruce J. Sargent, Ph.D., newly appointed to senior vice president, drug discovery.
A
Under this reorganization, the company is combining its discovery chemistry and biology functions into a single unit across locations worldwide. Customers will better benefit from AMRI’s experience in per- forming fully coordinated multidisciplinary disco- very projects utilizing a global network of scientific experts, laboratories and equipment in medicinal chemistry, biology and/or ADMET.
http://www.amriglobal.com
Nalamasu to Chief Technology Officer (CTO) for the Company, effective January 24, 2011. Dr. Nala- masu will report to chairman and CEO Mike Splinter and will provide critical insight to further enhance Applied’s technology leadership in the industries it serves.
A
2010 fourth quarter and year ended September 30, 2010. For the fiscal year ended September 30, 2010, Arrowhead reported revenues of $620,000, compa- red with $3.8 million for the fiscal year ended Sep- tember 30, 2009. Net loss attributable to Arrowhead for the 2010 fiscal year was $5.8 million, or $0.09 per share based on 64.3 million weighted average shares outstanding, compared with a net loss attri-
A
http://www.appliedmaterials.com
rrowhead Research Corporation (NASDAQ: ARWR) announced financial results for its fiscal
pplied Materials, Inc. (NASDAQ: AMAT) an- nounced the promotion of Dr. Omkaram (Om)
MRI (NASDAQ: AMRI) announced the merging of its Discovery R&D and Discovery Chemistry
butable to Arrowhead of $19.3 million, or $0.43 per share based on 45.2 million weighted average shares outstanding in fiscal 2009. Full year operating ex- penses decreased by 60% from $23.3 million in fiscal 2009 to $9.4 million in fiscal 2010. The Company’s net cash used in operations for fiscal 2010 was $7.7 million, compared with $15.1 million in fiscal 2009. Cash provided by financing activities was $12.0 million, primarily due to proceeds from the issuan- ces of equity and warrants of $12.8 million offset by payments on capital lease obligation of $0.7 million. As of September 30, 2010, Arrowhead had cash and cash equivalents of $6.8 million and stockholders’ equity of $8.1 million. In 2010, 1. Arrowhead consolidated its ownership interest in Calando and simplified Calando’s capital structure through investment, conversion of debt, and acquisi- tion of minority interest.
2. Calando continued to enroll patients in its Phase I cancer trial and build relationships with potential partners and acquirers.
3. Unidym entered into IP cooperation and licensing agreements with Samsung Electronics generating revenue of $4.5 million in December 2010, allevi- ating Arrowhead of funding obligations for Unidym operations.
4. Nanotope entered into its first development partnership with Smith & Nephew, a global leader in medical technology, for up to $26.55 million in milestone payments plus potential sales royalties.
5. Arrowhead formed a new subsidiary, Ablaris Therapeutics, Inc., to commercialize obesity fighting therapeutics.
13
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95